Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/199760
Type: Artigo de periódico
Title: Brazilian Experience Using High Dose Sequential Chemotherapy Followed By Autologous Hematopoietic Stem Cell Transplantation For Malignant Lymphomas.
Author: Duarte, Bruno Kosa Lino
Miranda, Eliana Cristina Martins
Nucci, Marcio
Vigorito, Afonso Celso
Penteado, Francisco José
Marques, José Francisco Comenalli
Oliveira-Duarte, Gislaine Borba
Lorand-Metze, Irene Gyongyver Heidemarie
Pagnano, Katia Borgia
Delamain, Marcia Torresan
Baldissera, Renata
Valente, Isabella Salvetti
de Souza, Carmino Antonio
Abstract: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. High-dose cyclophosphamide followed by autologous hematopoietic stem cell transplantation is an effective and feasible therapy for refractory/relapsed lymphomas; this regimen has never before been evaluated in a Brazilian population. All patients (106 with high-grade non-Hodgkin lymphoma and 77 with Hodgkin's lymphoma) submitted to this treatment between 1998 and 2006 were analyzed. Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m(2)) and granulocyte-colony stimulating factor (300 µg/day), followed by peripheral blood progenitor cell harvesting, administration of etoposide (2g/m(2)) and methotrexate (8 g/m(2) only for Hodgkin's lymphoma) and autologous hematopoietic stem cell transplantation. At diagnosis, non-Hodgkin lymphoma patients had a median age of 45 (range: 8-65) years old, 78% had diffuse large B-cell lymphoma and 83% had stage III/IV disease. The Hodgkin's lymphoma patients had a median age of 23 (range: 7-68) years old, 64.9% had the nodular sclerosis subtype and 65% had stage III/IV disease. Nine Hodgkin's lymphoma patients (13%) and 10 (9%) non-Hodgkin lymphoma patients had some kind of cardiac toxicity. The overall survival, disease-free survival and progression-free survival in Hodgkin's lymphoma were 29%, 59% and 26%, respectively. In non-Hodgkin lymphoma, these values were 40%, 49% and 31%, respectively. High-dose cyclophosphamide-related mortality was 10% for Hodgkin's lymphoma and 5% for non-Hodgkin lymphoma patients. High-dose cyclophosphamide dosing had no impact on toxicity or survival for both groups. Despite a greater prevalence of poor prognostic factors, our results are comparable to the literature. The incidence of secondary neoplasias is noteworthy. Our study suggests that this approach is efficient and feasible, regardless of toxicity-related mortality.
Subject: Antineoplastic Combined Chemotherapy Protocols/administration & Dosage
Cyclophosphamide/administration & Dosage
Hematopoietic Stem Cell Transplantation
Hodgkin Disease/drug Therapy
Lymphoma
Lymphoma, Non-hodgkin
Transplantation, Autologous
Rights: aberto
Identifier DOI: 10.5581/1516-8484.20110118
Address: http://www.ncbi.nlm.nih.gov/pubmed/23049359
Date Issue: 2011
Appears in Collections:Artigos e Materiais de Revistas Científicas - Unicamp

Files in This Item:
File SizeFormat 
pmed_23049359.pdf831.95 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.